BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 27011303)

  • 1. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
    Maino E; Bonifacio M; Scattolin AM; Bassan R
    Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
    Aldoss I; Forman SJ
    Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should immunologic strategies be incorporated into frontline ALL therapy?
    Rank CU; Stock W
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
    Wei G; Wang J; Huang H; Zhao Y
    J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
    Kantarjian H; Jabbour E
    Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
    Le Jeune C; Thomas X
    Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
    Barsan V; Ramakrishna S; Davis KL
    Curr Oncol Rep; 2020 Jan; 22(2):11. PubMed ID: 31997022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
    Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
    J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.